Healthcare Self‑Reliance: India Now Manufactures 54 Life‑Saving Medical Devices

India’s MedTech manufacturing ecosystem has expanded to produce 54 unique medical technology products, ranging from advanced cancer-treatment equipment like Linear Accelerators (LINAC) to life-saving cardiac stents, under the government’s Production Linked Incentive (PLI) scheme.

Under the PLI Scheme for medical devices, 21 projects have started manufacturing of 54 unique medical devices, which include high end devices such as Linear Accelerator (LINAC), MRI, CT-Scan, Heart Valve, Stent, Dialyzer Machine, C-Arm, Cath Lab, Mammograph, MRI Coils, etc.

India’s MedTech Leap

• Scope of Products: India now manufactures 54 distinct MedTech devices, covering oncology (LINAC machines), cardiology (stents), imaging, diagnostics, and surgical equipment.
• Strategic Goal: Diversifies production, reduces import dependence, and strengthens domestic healthcare infrastructure.
• Policy Driver: The Production Linked Incentive (PLI) scheme has been central to this achievement.

📊 Why This Matters

• Healthcare Access: Domestic production lowers costs and improves availability for hospitals and patients.
• Economic Impact: MedTech contributes to India’s manufacturing revival, with ₹2 lakh crore in investments realized across PLI sectors by September 2025.
• Global Competitiveness: India is emerging as a hub for affordable MedTech exports.

Challenges & Trade-offs

• Quality Standards: Competing globally requires strict adherence to FDA and CE certifications.
• Supply Chain: Raw materials and specialized components may still rely on global suppliers.
• Innovation Gap: Sustained R&D investment is needed to match Western innovation.

Strategic Outlook

• Domestic Impact: Hospitals across India gain access to advanced devices like LINAC machines for cancer therapy.
• Export Potential: Affordable stents and diagnostic devices can boost India’s role in global healthcare supply chains.
• Policy Continuity: Continued government support through PLI and regulatory reforms will be critical.

In short:

India’s ability to manufacture 54 unique MedTech products—from LINACs to stents—signals a major step toward healthcare self-reliance and global competitiveness.

Tata Elxsi and Bayer Unveil Radiology Development Centre to Fast-Track Diagnostic Innovation

Tata Elxsi, a global leader in design and technology services, today announced the inauguration of the ‘Bayer Development Centre in Radiology’ at Tata Elxsi, Pune, India. The centre is designed to co-develop with Bayer, a leader in key areas of Radiology, advanced radiology devices and technology that enable early and accurate diagnosis and treatment of critical illnesses, supporting Bayer’s global mission to bring innovative, safe, and compliant solutions to patients and clinical staff worldwide.

This centre will provide a wide range of engineering for complex radiology devices, with an initial focus on Molecular Imaging. The facility’s integrated approach, which combines design, development, and validation, the centre will help accelerate time-to-market, enhance cost efficiency, and help deliver new technology to market fast, efficiently, and at an optimized cost, while meeting highest regulatory compliance standards.

This collaboration leverages Tata Elxsi’s healthcare engineering expertise and the strength of the Tata and India ecosystems—enabling access to advanced labs, regulatory partnerships, and specialised technology talent. This creates a scalable foundation for innovation and strengthens Bayer’s ability to deliver radiology solutions across multiple geographies, including the US and EU.

Dr. Konstanze Diefenbach, Head of Research & Development, Radiology, Bayer, commented: “Bayer is committed to innovative products and high-quality services in diagnostic imaging, and device innovation plays a critical role in delivering precision and safety in patient care. This new centre gives us direct access to specialised engineering capabilities through Tata Elxsi, enabling us to accelerate our pipeline of advanced radiology devices while maintaining the quality and reliability that healthcare providers expect from Bayer.”

Sreevatsa Sahasranaman, Sr. Vice President & Head – Healthcare & Life Sciences, Tata Elxsi, said, “This centre is more than an engineering hub—it is where Bayer’s radiology vision meets Tata Elxsi’s design, AI/ML, and regulatory expertise. Our teams will work together to translate ideas into devices that address real-world diagnostic challenges, with the assurance of safety, compliance, and global scalability.”

About Tata Elxsi

Tata Elxsi is a global design and technology services company headquartered in Bangalore. It addresses the healthcare, automotive, broadcast, and communications consumer electronics industries. This is supported by a network of design studios, development centres, and offices worldwide. Tata Elxsi's Healthcare & Life Sciences practice is ISO 13485 certified and collaborates with prominent medical device and pharmaceutical OEMs, as well as technology companies. With a comprehensive services and solutions portfolio, Tata Elxsi adds value at every stage of the customer's product development lifecycle. Recognised as a leader in technology consulting, new product design, development, verification & validation, as well as regulatory compliance services, Tata Elxsi is a trusted name in the industry. For more information, visit tataelxsi.com

IIT Bombay’s BETIC Gets ₹70 Cr Boost from ICICI Foundation to Advance Biomedical R&D

Indian Institute of Technology (IIT) Bombay and ICICI Foundation for Inclusive Growth (ICICI Foundation), the CSR arm of ICICI Bank, have forged a partnership to expand the biomedical innovation hub at the country’s premier technology and engineering institute. Under this partnership, ICICI Foundation has pledged ₹70 crore to set up additional floors at the Biomedical Engineering and Technology Innovation Centre (BETIC) at IIT Bombay and equip this area with advanced facilities.

The MoU was signed by Prof. Shireesh Kedare, Director, IIT Bombay and Mr. Sanjay Datta, President, ICICI Foundation in presence of Mr. Pradeep Kumar Sinha, Chairman, ICICI Bank.

The new floors, named ‘IIT-ICICI BETIC Hub’, will significantly expand IIT Bombay’s capabilities in biomedical engineering, increasing its space five-fold to 19,700 sq. ft. The hub will foster collaboration among researchers, clinicians, and industry leaders to develop affordable, cutting-edge medical devices and diagnostic solutions. It will be equipped with state-of-the-art resources for product development, medical grade manufacturing, safety testing, inspection, and packaging. This enhanced ecosystem will support med-tech startups and companies, train professionals in healthcare innovation, and generate high-value jobs, ultimately benefiting millions of patients.

Speaking on the collaboration, Prof. Shireesh Kedare, Director, IIT Bombay, said, "This partnership exemplifies how industry-academia alliances can drive innovation towards real-world impact. With ICICI Foundation’s generous support, IIT Bombay is poised to revolutionise biomedical research and technology, addressing critical healthcare gaps in India, fostering home-grown solutions that are accessible, affordable, and scalable.”

Commenting on the partnership, Mr. Pradeep Kumar Sinha, Chairman, ICICI Bank, said, “Healthcare is a key focus at ICICI Foundation’s CSR initiatives. India’s unique healthcare challenges -- high disease burden, vast rural populations, and affordability constraints—demand indigenous innovations in biomedical, tailored to its needs. Homegrown advancement will not only reduce dependency on imports but also foster cost-effective, cutting-edge medical solutions that can empower healthcare professionals and benefit millions across the country. The partnership between ICICI Foundation and IIT Bombay aims to meet this objective. The ‘IITB-ICICI BETIC Hub’ will facilitate the development of indigenous medical innovations ensuring affordable healthcare solutions to patients. We are delighted to collaborate with IIT Bombay to drive a meaningful change in the healthcare ecosystem.”

So far, ICICI Foundation has positively impacted over 2.5 million lives to receive treatment in 550 hospitals across the country through its initiatives in the healthcare sector. This includes building capacity in curative care, including cancer care, cardiac care, eye care, trauma and emergency care.

About BETIC:

BETIC is the only lab in an academic setting in India with ISO 13485 certification—an internationally recognised quality management system standard for medical devices. It has identified 450 unmet needs after detailed discussions with hundreds of doctors across various specialisations, created 240 novel prototypes, and has filed 70 patents. It has developed 43 medical devices, out of which 23 have been taken to market by startups formed at BETIC; while the remaining 20 devices have been licensed to Indian companies. A recipient of 61 prestigious awards, BETIC has impacted several million lives till date. For more details on BETIC’s work, visit Medical Device Innovation –BETIC, Mumbai

German MedTech Firm Dräger Establish ODC at Tata Elxsi's Pune Facility

Tata Elxsi and Dräger, a global leader in medical and safety technology, have announced an innovative partnership to drive critical care innovation in India.

As part of this collaboration, Dräger is expanding its research and development presence by establishing a new Offshore Development Center (ODC) at Tata Elxsi's facility in Pune.

The ODC will focus on developing innovative critical care medical devices for both local and international markets. This partnership combines Tata Elxsi's design and technology expertise with Dräger's expertise in medical and safety technology.

The development center will unite talent from both organizations, dedicated to designing and developing innovative critical care medical devices for deployment in the Operation Theatre (OT) environment worldwide. The ODC provides a comprehensive critical care equipment testing facility, equipped with medical-grade gases, compressors, and oxygen cylinders to create a test environment that meets the demanding requirements of the OT setup.

This collaboration aims to push the boundaries of medical innovation, adhering to the highest safety and efficacy standards for critical care settings. It showcases Indian R&D capabilities on the global stage and marks Dräger's second R&D center in India. The partnership underscores the strategic importance of India as an R&D hub and sets new standards in critical care equipment development.

Dräger is a German company based in Lübeck that specializes in breathing and protection equipment, gas detection and analysis systems, and non-invasive patient monitoring technologies. Their products are used by hospitals, fire departments, and diving companies worldwide.

Founded in 1889, Dräger has grown into a global enterprise with over 16,000 employees and a presence in more than 190 countries. In 2023, the company generated net sales of approximately EUR 3.4 billion. Their commitment to safety and innovation makes them a significant player in critical care technology.

Tata Elxsi's Healthcare & Life Sciences practice is ISO 13485 certified and collaborates with prominent medical device and pharmaceutical OEMs, as well as technology companies. With a comprehensive services and solutions portfolio, Tata Elxsi adds value at every stage of the customer's product development lifecycle.

 

Health Ministry Launches MedTech Mitra To Strengthen India's Medical Device Industry

Union Minister, Health & Family Welfare, Dr. Mansukh Mandaviya has, on Monday, inaugurated "MedTech Mitra," a groundbreaking initiative by ICMR Delhi and Central Drugs Standard Control Organisation (CDSCO), supported by Niti Aayog.

MedTech Mitra will hand-hold innovators and help them in getting regulatory approval. This new platform, along with the recent medical devices policy and the production-linked incentive scheme, will together provide a boost to the medical devices sector and encourage domestic manufacturing of these devices, the minister said.

MedTech Mitra streamlines MedTech R&D with preclinical & clinical support, collaboration initiatives, & funding opportunities. It is a primary step towards building a robust, self-reliant ecosystem for affordable & accessible healthcare in India.

Dr. Mansukh Mandaviya said, "MedTech Mitra is a platform that will help the young talents of the country by holding their hands and giving them final shape to their research, knowledge, logic and help them in getting regulatory approval."

"The medical devices sector is an essential and integral constituent of India’s healthcare sector. Pursuing the vision of Viksit Bharat, India is taking a holistic approach to health with a vision to transform the health landscape in the country by 2047, " added Dr. Mandaviya.

MedTech Mitra will empower emerging start-ups and ensure ease of innovation, ease of doing research and development, ease of rendering service in building an Atmanirbhar Bharat.

Highlighting the fast pace of growth in technology, Dr. Mandaviya added “Due to the developments taking place in sectors like Robotics, Artificial Intelligence, Big Data, Virtual Reality, Nano Technology, the medical device sector is changing rapidly today.”

Lauding the initiative and efforts of the innovators and youth, Dr. Mandaviya stated “There is immense power among the innovators, researchers and start-up youth in the country who know how to do Research and Logic Development. If one gets help at the approval stage itself, then wonders can be achieved which will take India miles ahead in becoming Atmanirbhar and achieving the vision of Viksit Bharat”

Underlining the alignment of MedTech Mitra with the medical devices ecosystem as well as overall boosting the growth and development of health domain, Dr. V.K Paul, Member Health, Niti Aayog, said, “This platform will serve to strengthen India’s commitment to Universal Health Coverage, further consolidating reach of healthcare services to the innermost corners of the nation to become an integral aspect of Viksit Bharat.”

Earlier this month, ICMR signed a Memorandum of Agreement with AcSIR (Academy of Scientific and Innovative Research) for a new faculty of "Medical Research" that has been created at AcSIR. This is a significant development towards making AcSIR a multi-disciplinary Research Institution for promotion of cutting-edge research in cross-disciplinary areas. This would provide much needed impetus to the medical research in India.

IIT Kanpur-Incubated Noccarc Gets ₹3.94 Cr in TDB-DST Funding for Commercialization of Digitally-enabled Advanced Universal ICU Ventilator

Technology Development Board (TDB), a statutory body established by Government of India, has entered into an agreement with Indian Institute of Technology (IIT) , Kanpur incubated startup — Noccarc — which is dedicated to the commercialization of Digitally Enabled Advanced Universal ICU Ventilators.

TBD has pledged support of ₹3.94 Crores out of the total project cost of ₹7.89 Crores to Pune-based Noccarc for its indigenously developed technology innovation.

Incubated at the Startup Incubation and Innovation Centre (SIIC) of the IIT-Kanpur, Noccarc has indigenously developed the entire technology, with several patents filed for each component, of the ventilator. The company's entry-level ventilator, V310, played a critical role during the COVID-19 pandemic, being deployed in diverse hospitals across India, where it became instrumental in saving lives.

Noccarc V730i

Building on this success, Noccarc is now launching the Noccarc V730i, which is a smart ventilator. V730i allows seamless connectivity to the cloud via GSM, Wi-Fi, and LAN, allowing doctors and intensive care specialists to remotely monitor the patient data on Noccarc’s digital platform, and will also enable hospitals to digitize their ICU data and workflows.

This initiative is aligned with the Government's push towards creating a self-reliant India in the medical devices sector.

Founded in 2017, by IIT Kanpur graduates – Harshit Rathore and Nikhil Kurele, Noccarc (Formerly Nocca Robotics) is a medical device start-up company at the forefront of healthcare innovation. Its smart medical devices are just the beginning of our mission to transform the healthcare industry through technology.

In September 2019, Noccarc had raised INR 12.4 crore from IAN Fund and Indian Angel Network.

Speaking on this occasion, the Founders of Noccarc, Nikhil Kurele, and Harshit Rathore, expressed that the support and assistance from TDB would propel the company in its quest for technological indigenization across India's healthcare sector. They emphasized that Noccarc's endeavours would contribute significantly to the Atmanirbhar Bharat initiatives of the Government, setting a precedent for innovation and self-reliance in the field of medical technology.

Rajesh Kumar Pathak, Secretary, TDB said that, “Noccarc's innovations in advanced medical technology are a testament to India's capabilities in developing advanced solutions that cater to the needs of domestic healthcare facilities. M/s Noccarc focuses on commercializing Digitally Enabled Advanced Universal ICU Ventilators, which are expected to revolutionize the critical care industry. The company's manufacturing site in Pune is a symbol of the realization of digitally-enabled healthcare devices made in India, which have immense potential in export markets too.”

Notably, more than 85% of medical devices in India are imported, the push towards indigenously developed products is thus become more critical. The Government of India, under its "Make in India" initiative and a renewed focus on digitization across all sectors, including healthcare, is driving a robust ecosystem for homegrown Innovations like that of Noccarc. 

Pheezee, a Hyderabad Startup’s Physiotherapy Monitoring Device, a 1st of Its Kind in the World Receives USFDA

Pheezee is designed to assess musculoskeletal and neuromuscular health.

Startoon Labs Private Limited, a Hyderabad-based ISO 13485:2016 and ISO 9001:2015 Certified medical device R&D, Engineering and Manufacturing Company with a focus on Joint health received US FDA (The US Food and Drug Administration) (510 K Exempt) clearance for its revolutionary wearable device PHEEZEE®️.

The US FDA is a regulatory agency that ensures the safety and security of drugs, devices and other products going into the US Market.

Disclosing this in a press note issued in Hyderabad, Suresh Susurla, Founder & CEO said, Pheezee is a patented technology, capable of measuring the surface Electromyogram (sEMG) of bulk muscles and Range of motion (ROM) of primary joints simultaneously, to determine joint health, making it a one-of-a-kind product in the world with this capability.

Pheezee is helpful in assessing joint health during physiotherapy post musculoskeletal, neurological, spinal cord injuries and neuro-ailments such as paralysis, hemiplegia, paraplegia, muscular dystrophy etc. It generates reports, for the first time in the field of physiotherapy, enabling patients to track their recovery. Pheezee, being an IOT-enabled device, enables telerehabilitation of the patients and allows them to continue doing physiotherapy sessions at home and still keep the referring surgeon updated about the progress.

It is a revolutionary device set to transform the way assessments, monitoring and tracking of recovery is done in the field of physiotherapy, says Mythreyi Kondapi Co-founder of the medical technology startup.

The flagship product of the company already enjoys national and international recognition. With USFDA’s nod, its reach is going to be widened even further. Now it will demonstrate its performance in the USA and many other global markets. Utilizing advanced technology like Electromyography and Range of Motion monitoring, Pheezee®️ measures and tracks the recovery of patients post musculoskeletal and neurological ailments. The device finds usage in joint health assessments in multiple musculoskeletal diseases, including arthritis, muscle dystrophy, carpal tunnel syndrome (which affects 64.4% of IT professionals), and many more in their early stages.

It is a proud moment not just for us, but for the entire medtech startup community in the state that Pheezee is now a globally accepted Made in Telangana product. What could be a better moment than this for us at Startoon Labs to see our product go global, said Suresh, a well-acclaimed professional who has 11 international publications to his credit (co-authored).

Startoon Labs is one of the most vibrant startups among 4,000 startups in Telangana.

Pheezee®️ is certified for electrical and environmental safety as per international standards and is a registered medical device with CDSCO – the Regulatory body of Govt. of India. The device is a game-changer in the field of physiotherapy and rehabilitation, Suresh adds.

As a part of the rapidly growing MedTech industry in India, valued at $10.86 billion in 2020, Startoon Labs is at the forefront of the digital technology segment. The sector is poised for growth, at a CAGR of 37% and to reach $50 billion by 2025, he adds.

The major driving forces behind this growth are the Government’s support, increased public spending, penetration of healthcare and internet, medical tourism, growing population, and increased disposable income. Digital technology in the global healthcare sector is estimated to save between $1.5 trillion and $3 trillion by 2030, making it a highly attractive investment opportunity.

National Medical Devices Policy'23 Expected To Boost Sector from Present $11 Bn to $50 Bn in Next 5 Years

Centres of Excellence in academic and research institutions, innovation hubs, ‘plug and play’ infrastructures and support to start-ups

Six Strategies planned to tap the potential of the Sector, with the Implementation Action Plan

The Union Cabinet, chaired by the Hon'ble Prime Minister Shri Narendra Modi, has approved the National Medical Devices Policy, 2023, on Wednesday this week. 

The medical devices sector in India is an essential and integral constituent of the Indian healthcare sector. The Indian medical devices sector’s contribution has become even more prominent as India supported the domestic and global battle against COVID-19 pandemic through the large scale production of medical devices & diagnostic kits, such as Ventilators, Rapid Antigen Test kits, Real-Rime Reverse Transcription Polymerase Chain Reaction (RT-PCR) kits, Infrared (IR) Thermometers, Personal Protective Equipment(PPE) Kits & N-95 masks.

The medical devices sector in India is a sunrise sector which is growing at a fast pace. The market size of the medical devices sector in India is estimated to be $11 billion (approximately, ₹ 90,000 Cr) in 2020 and its share in the global medical device market is estimated to be 1.5%.

The Indian medical devices sector is on a growth track and has an enormous potential to become self-reliant and to contribute towards the goal of universal health care. The Government of India has already initiated implementation of PLI Scheme for medical devices and support for setting up of 4 Medical devices Parks in the States of Himachal Pradesh, Madhya Pradesh, Tamil Nadu and Uttar Pradesh.

The National Medical Devices Policy, 2023 is expected to facilitate an orderly growth of the medical device sector to meet the public health objectives of access, affordability, quality and innovation. This sector is expected to realize its full potential, with the strategies viz, building an enabling ecosystem for manufacturing along with a focus on innovation, creating a robust and streamlined regulatory framework, providing support in training and capacity building programs and promoting higher education to foster talent and skilled resources in line with the industry requirements. Encouraging domestic investments and production of medical devices complements the Government’s ‘Atmanirbhar Bharat’ and ‘Make in India’ programs.

Salient Features of National Medical Devices Policy, 2023:

Vision: Accelerated growth path with a patient-centric approach and to emerge as the global leader in the manufacturing and innovation of medical devices by achieving 10-12% share in the expanding global market over the next 25 years. Policy is expected to help the Medical Devices Sector grow from present $11 Bn to $50 Bn by 2030.

Mission: Policy lays down a roadmap for accelerated growth of the medical devices sector to achieve the following missions viz, Access & Universality, Affordability, Quality, Patient Centred & Quality Care, Preventive & Promotive Health, Security, Research and Innovation and Skilled manpower.

Strategies to Promote Medical Device Sector:

Medical devices sector will be facilitated and guided through a set of strategies that will be cover six broad areas of policy interventions:

• Regulatory Streamlining: In order to enhance ease of doing research and business and further to balance patient safety with product innovation measures such as creation of a Single Window Clearance System' for Licensing of Medical Devices coopting all the stakeholder departments / organizations such as AERB, MeitY, DAHD, etc, enhancing the Role of Indian Standards like BIS and designing a coherent pricing regulation, will be followed.

• Enabling Infrastructure: The establishment and strengthening of large medical device parks, clusters equipped with world class common infrastructure facilities in proximity to economic zones with requisite logistics connectivity as envisioned under the National Industrial Corridor Program and the proposed National Logistics Policy 2021 under the ambit of PM Gati Shakti, would be pursued with the State Governments and Industry for better convergence and backward integration with medical device Industry. 

• Facilitating R&D and Innovation: The policy envisages to promote Research & Development in India and complement the Department’s proposed National Policy on R&D and Innovation in the Pharma- MedTech Sector in India. It also aims at establishing Centres of Excellence in academic and research institutions, innovation hubs, ‘plug and play’ infrastructures and support to start-ups.

• Attracting Investments in the Sector: Along with resent schemes and interventions like Make in India, Ayushman Bharat program, Heal-in-India, Start-up mission, the policy encourages private investments, series of funding from Venture Capitalists, and also Public-Private Partnership(PPP).

• Human Resources Development: In order to have a steady supply of skilled work force across the value chain such as scientists, regulators, health experts, managers, technicians, etc., the policy envisages:

• For skilling, reskilling and upskilling of professionals in the medical device sector, we can leverage the available resources in Ministry of Skill Development and Entrepreneurship.
• The policy will support dedicated multidisciplinary courses for medical devices in existing institutions to ensure availability of skilled manpower for futuristic medical technologies, high-end manufacturing and research, to produce future-ready MedTech human resources and to meet the evolving needs of the Sector
• To develop partnerships with foreign academic/industry organizations to develop medical technologies in order to be in equal pace with the world market.

• Brand Positioning and Awareness Creation: The policy envisages the creation of a dedicated Export Promotion Council for the sector under the Department which will be an enabler to deal with various market access issues:

• Initiate studies and projects for learning from best global practices of manufacturing and skilling system so as to explore the feasibility of adapting such successful models in India.
• Promote more forums to bring together various stakeholders for sharing knowledge and build strong networks across the sector.

The policy is expected to provide the required support and directions to strengthen the medical devices industry into a competitive, self-reliant, resilient and innovative industry that caters to the healthcare needs of not only India but also of the world. The National Medical Devices Policy, 2023 aims to place the medical devices sector on an accelerated path of growth with a patient-centric approach to meet the evolving healthcare needs of patients.

Under the PLI scheme for Medical Devices, till now, a total of 26 projects have been approved, with a committed investment of Rs.1206 Cr and out of this, so far, an investment of Rs.714 Cr has been achieved. Under the PLI scheme, total of 14 projects producing 37 products have been commissioned and domestic manufacturing of high-end medical devices has started which include Linear Accelerator, MRI Scan, CT-Scan, Mammogram, C-Arm, MRI Coils, high end X-ray tubes, etc. Remaining 12 products will be commissioned in near future.

Five projects out of total 26 projects have been approved recently, under Category B, for domestic manufacturing of 87 products / product components.

Building upon these measures, a holistic policy framework to accelerate this growth and fulfil the potential of the sector is the need of the hour. While various Departments of the Government have undertaken programmatic interventions to encourage the sector, the current policy aims to put in place a comprehensive set of focus areas for growth of the sector in a coordinated manner.

Secondly, in view of the diversity and multi-disciplinary nature of the sector, the regulations, skilling trade promotion of medical device industry are spread over several departments in the Government both at the Centre and State levels. There is a need to bring together the range of interventions in a coherent manner that would facilitate focused and efficient support and facilitation for the sector by the respective agencies.

Healthcare Co. QMS MAS Forays Into D2C Sector; Launches Q Devices, Unveils Path Breaking Medical Wearable Vyana in Partnership With Varanium Cloud Ltd

• Q devices include point-of-care lifestyle monitoring products, including multifunction fingertip health monitors, mesh nebulisers, and more
• The event was graced by legendary cricketer Kapil Dev and Bollywood star Esha Deol. 

QMS MAS (Medical Allied Services), a front-runner in the field of health care and wellness made its maiden foray into the direct-to-consumer sector, launching a vast range of point-of-care products under the banner Q Devices. The event also witnessed the unveiling of a revolutionary medical wearable, Vyana in collaboration with Varanium Cloud Ltd., India’s leading digital technology company. Vyana aims to address a growing need of having a medical wearable that aids timely assistance and it has been designed to constantly monitor vital parameters and send instant notifications as well as contact the user and their emergency contacts directly in case of significant fluctuations, thereby making it a must use for high risk groups.

The event which was graced by the legendary cricketer, Kapil Dev and Bollywood star, Esha Deol also saw the presence of Mahesh Makhija, Chairman & MD along with Dr. Guddi Makhija, Director, QMS MAS. An array of medical devices was launched under the umbrella of Q Devices ranging from multifunction fingertip health monitors, mesh nebulisers, personal massagers, tubular mattresses with compressors, automatic blood pressure monitors, digital thermometers, powered suction pumps and nano steamers. These lifestyle monitoring devices offered by the brand meet the highest standards of quality and resonate with the company’s mission of advocating a healthier lifestyle amongst its consumers. These products are available in offline stores as well as online platforms like Amazon and their own website (QDevices.life).

Speaking at the launch, Dr. Guddi Makhija said, “The company’s prerogative has always been to help customers adopt a healthy lifestyle. Q devices offer products that will serve as dependable allies in the customer’s healthcare journey. Especially salient in this regard is Vyana, a first-of-its-kind device that we have launched in partnership with Varanium Cloud Ltd. These lifestyle monitoring products are a culmination of the hard work, a spirit of scientific inquiry and innovation that QMS MAS has fostered over 28 years. They are reliable, dependable and easy to use, and through them, we hope to realise our dream of making India healthier and happier.”

Harshawardhan Sabale, Managing Director, Varanium Cloud Ltd said “We are delighted to partner with QMS MAS to unveil Vyana. This device will help address the health concerns of millions of Indians and help reduce the number of hospitalisations due to avoidable reasons by alerting people on time about their fluctuating biological indicators. It’s a technological breakthrough for us and we hope to serve as many people as we can with its launch in the coming days.

Kapil Dev said, “It is indeed a very proud moment for me to be witnessing the launch of Q Devices considering that healthcare needs to be the first priority for any individual and QMS has taken a big stride today in achieving that goal and making vital medical devices easily accessible to everyone, all at the click of a mouse. Through this momentous step forward, QMS has ensured that the most advanced healthcare equipment and services are available, ensuring customer welfare and wellbeing that is at the core of the brand’s philosophy. This will also be instrumental in paving the way for the healthcare landscape to further evolve in terms of patientcare as well as in optimising treatment outcomes.”

Multifunction Fingertip Health Monitor

This product allows users to measure oxygen saturation and continuous blood pressure by applying the device to their fingertips. The readings are customised as per age and weight. An adjustable four-direction display makes it the perfect metric measurement partner during workout sessions.
Mesh Nebulizer

These Mesh nebulisers have a distinct advantage over regular nebulisers, making them easier to carry and offering greater energy efficiency and lung deposition. They come with pediatric and adult masks and an in-built battery system that can be charged via the USB cable provided.

Personal Massager

This portable and easy-to-use personal massager comes with four multifunctional interchangeable heads, including a flat massage head which can be used to massage the face and abdominal areas, a dead skin massage head which can remove dead skin with a gentle scrubbing motion, a wavy massage head which is effective in eliminating muscle fatigue, and a ball massage head which is helpful for deep tissue massage for improved blood flow.

Tubular Mattress with Compressor/Alternate Pressure System

This is the best ally for patients advised bed rest as it helps them avoid bed sores. It can bear a load of over 120 kg and be used for 24 hours straight.

Automatic Blood Pressure Monitor

This highly accurate, easy-to-use monitor uses oscillometric technology to measure systolic and diastolic blood pressure and pulse rate.

Digital Thermometer

This digital thermometer boasts of one-touch operation and ease of use. It is unbreakable and equipped with a beep alarm to notify the cessation of measurement.

Powered Suction Pump

This product can be used when an individual suffers from a moist cough. It allows them to clear mucus obstruction from the throat, thus helping maintain airflow. This suction pump includes a vacuum meter, pumps, pressure regulating, liquid holder and air filter.

Nano Steamer

This nano steamer is helpful for steam inhalation to remedy nasal congestion, allergies, cough and cold in adults and children. It can also be used as a facial steamer in one’s skincare routine.

About QMS MAS:

Founded in 1994 by stalwarts like Mr. Mahesh Makhija and Dr. Guddi Makhija, QMS MAS has proved its merit in the B2B segment and has propositioned to transition into a healthcare enterprise in the direct-to-consumer domain, with its point-of-care-products, under the banner Q devices. The brand, true to its tagline ‘Count On Us’, employs the latest technology to help clients in their journey toward good health and wellness.

About Varanium Cloud Ltd.:

Varanium Cloud Ltd is a digital technology firm started in 2017 with an aim to extend digital solutions to users from non-urban agglomerations by mitigating technological gaps through the introduction of new-age digital tools that create equal opportunities. Headquartered in Mumbai, Varanium offers an extensive array of digital solutions through its subsidiaries. The company’s primary services include Edtech, Edge Data Centres for reliable computing in non-urban cities, Software-as-a-service (SaaS) and eCommerce-as-a- Service (EaaS).

ISB-Incubated Company S3V Vascular Comes Out with New-age Neuro Medical Devices Useful in Reversing Paralysis

Dr.Vijay, N.G. Badari Narayan and M.V Gowthama

The plant for manufacturing the same will be designed and built as per USFDA norms.

While 20 lakh brain strokes take place in India each year, just 1500 only go to the Interventional procedures. 

S3V is striving to bring high-end stroke treatment technology to the common man

S3V Vascular Technologies, a company incubated at the Indian School of Business, Hyderabad in 2011 by Alumni of the PGPMAX founding batch has come out with India’s first and revolutionary medical devices useful in reversing paralysis. They include Neuro Clot Retriever, Neuro Aspiration Catheter, and Neuro Microcatheter. These devices will be formally launched in Hyderabad by Dr Tamilisai Soundararajan, at a function in the city on 15th December.

Prof Balram Bhargava, Chief of Cardiothoracic Sciences, AIIMS, New Delhi & former Director General of ICMR and Dr Mathew Cherian, Past president of the Indian society of vascular and interventional radiology will also participate and grace.

S3V for the past few years has been working on the design and development of the Hardware used in Mechanical Thrombectomy.

Giving details, addressing the press conference Mr. N.G. Badari Narayan founder and Head of Medical Devices at S3V and formerly MD of Relisys, which was known for introducing Kalam-Raju stent, said about 20 lakh brain strokes take place in India each year. But only 1500 patients undergo procedures. With the launch of these futuristic products, we hope that the number of procedures may go up to at least 2.5 lakh per annum in the next decade. With these devices, if the procedures are done in time within the golden hour, there is a high chance for blood flow to be restored and paralysis reversed, he added.

Neuro Clot Retriever Neuro Aspiration Catheter Neuro Microcathete

Dr. Vijay, Mr. N.G. Badari Narayan and Mr. M.V Gowthama

The gold standard of treatment of ischemic brain stroke (stroke due to a blockage of brain vessels due to clot) is Mechanical Thrombectomy which involves an interventional procedure done in a cath lab to remove the clot stuck in the vessel of the brain.

Badari Narayan brings with him 32 years of medical device domain experience. Our endeavor is not only to introduce these products but also to make them affordable.

The company has received test licenses and soon will commence commercial production upon receiving the nod for manufacturing also, he added.

S3V is engaged in the development, manufacturing and marketing of a variety of Medical Devices, more particularly, Cardiac Devices, Neuro Devices, Nephro Devices, Onco Devices and Peripheral Devices. Now it is foraying into high precision Neuro Devices and electronics based catheters. It focuses on the manufacturing of NextGen medical devices indigenously. The neuro devices we are talking about are manufactured only by a handful of two or three countries all over the world. These are the state-of-the-art, highly advanced stents brought out only by us informed Mr. M.V. Gowthama, Director of the company who is the former CMD of Bharat Electronics Limited (BEL). Mr. Gowthama brings with him the core expertise in the design, development and manufacturing of critical electronic products.

Both the Directors are from Telugu states. S3V has its manufacturing facility at Mysore. The new manufacturing facility will come in Mysore District. The Government of Karnataka has allotted 8.81 acres of land. The new plant will be designed and built as per USFDA norms. The new facility will house cutting-edge technologies for integrated manufacturing. The company is likely to invest INR 200 Crore in the new plant.

Stroke also causes maximum disability leading to partial or complete paralysis in a patient next only to Road Traffic Accidents in India. Of all the strokes, 87% of strokes are due to a thrombus. Stroke not only affects the elderly but is increasingly being seen in individuals in the 35-50 age group due to lifestyle modifications.

Lack of Patient awareness, lack of trained manpower, high cost of hardware and lack of government reimbursement schemes are a hindrance to treatment with this procedure. The Current cost of the Hardware costs nearly INR 5 lakhs and the total procedure cost is between INR 8 to 12 Lakhs. Currently, the procedure covers less than 1% of the Stroke patient as more than 99% of Indians can’t afford this procedure.

S3V is striving to bring high-end stroke treatment technology to the common man. The challenge India faces starts from a lack of awareness, affordable hardware and availability of trained manpower in the form of intervention physicians. S3V is trying to address the entire ecosystem of this challenge.

Mumba-based HealthTech Co. Cognota Receives US FDA Approval for BP Monitor Device

Representational

• It’s a significant milestone in Cognota’s efforts to tap burgeoning medical devices market globally
• The approval broadens Cognota’s portfolio; puts it in good stead with both hardware & IT solutions

Leading healthtech company Cognota Healthcare on Monday announced that the United States Food and Drug Administration (US FDA) has approved the company’s blood pressure monitor device- ‘COGNOHEALTH Blood Pressure Monitor’, marking the successful foray of the company into the medical devices segment.

The regulatory approval is a significant milestone for Cognota which can now export its blood pressure monitor devices to the US, Europe, and other overseas countries along with tapping the burgeoning Indian market.

The ‘COGNOHEALTH Blood Pressure Monitor’ device is powered by state-of-the-art technology that has been designed and developed by experts in Cognota’s R&D team. Approval from the US FDA, one of the apex healthcare regulatory bodies of the world, enables Cognota to expand its existing portfolio of healthtech solutions that include Remote Patient Monitoring (RPM), Teleconsultation Platform, and Smart ICU among others.

In a short span, Cognota has emerged as a market leader in multiple critical healthtech solutions by embedding cutting-edge software solutions in hardware devices. With such successful integration, its healthtech solutions are being increasingly adopted by several marquee healthcare providers across the world. US FDA approval is likely to provide further traction to the current momentum.

Estimates suggest that the blood pressure monitoring devices market size is likely to surpass around $2.66 billion by 2027 globally, at a CAGR of 8.56 per cent during the 2021 to 2027 period.

India is considered one of the top 20 markets for medical devices globally. The total market size is likely to touch $50 billion by 2025, according to some estimates. The sector has seen healthy growth owing to various initiatives of the Indian government including an emphasis on research and development (R&D) along with allowing 100 per cent FDI (Foreign Direct Investment) in the medical devices segment.

India is also a house to a huge caseload of high blood pressure patients. A recent report by the India Council for Medical Research showed that one in four adults in India suffers from hypertension and only 10 per cent of patients have their blood pressure under control. Cognota’s BP Monitoring device, therefore, has sound prospects in the Indian market in the coming years.

Commenting on the US FDA approval of Cognota’s BP Monitoring device, Sanjeev Dahiwadkar, Founder & CEO of Cognota Healthcare said, “Hypertension is a critical health problem across the world given the current lifestyle and expectations of people. This silent killer disease is also a huge problem in India after diabetes. Therefore, the US FDA approval of ‘COGNOHEALTH Blood Pressure Monitor’ device is a huge leap in Cognota’s efforts towards addressing this challenge. Built in-house by our R&D team, this approval also vindicates Cognota’s expertise in the successful integration of digital applications with advanced hardware components.”

“US FDA approval is a rigorous process that investigates all aspects of a healthcare device. Therefore, approval of the COGNOHEALTH Blood Pressure Monitor device is a feather in Cognota’s cap, which showcases Cognota’s technological depth, R&D bandwidth, and talent base,” he said.

Cognota Healthcare, headquartered in Mumbai, India provides secured cloud-based solutions in the healthcare IT space. It offers solutions like HIS, HMO, tele consulting, claims management, and other products for all stakeholders, resulting in both cost and process efficiency while improving security and connectivity. Cognota helps healthcare enterprises in their digital transformation journey through data analytics & decision augmenting dashboards. With customer centricity at heart, agility in execution, and being virtuous in dealings, Cognota has seen, rising adoption of its services among enterprises across India, Middle East & Africa.

Wipro GE Healthcare Launches Fully ‘Made in India’ CT System Under Govt's PLI Scheme

From left to right: Dr. Shravan Subramanyam, Managing Director, Wipro GE Healthcare; Srikanth Suryanarayanan, Head – Imaging, South Asia, GE Healthcare; Raghavendra Rao V S, Head- Sales, India & South Asia; Kazuhiko Sato, GM Performance and Value CT, Molecular Imaging and Computed Tomography, GE Healthcare.

Wipro GE Healthcare Launches ‘Made in India’ CT System to Strengthen Access to Quality Healthcare Across India

• Revolution Aspire CT System is manufactured at the company’s new plant launched under the government’s Production Linked Incentives (PLI) Scheme and is aligned to government’s vision of ‘Atmanirbhar Bharat’
• Aims at enabling access to quality diagnosis across India, including tier 2 & tier 3 cities
• Greater clinical efficiency with enhanced image quality and operational efficiency with upto 50% higher patient throughput*1

Wipro GE Healthcare, a leading global medical technology and digital solutions innovator, today, announced the launch of its next-generation Revolution Aspire CT (Computed Tomography) scanner. Revolution Aspire is an advanced imaging solution designed and manufactured end-to-end in India, at the newly launched Wipro GE Medical Devices Manufacturing plant, in line with ‘Atmanirbhar Bharat’ initiative. The CT system is equipped with higher imaging intelligence to improve clinical confidence when diagnosing diseases and anomalies.

India faces a dual challenge of urban-rural divide and disease burden. Even though a major proportion of the population lives in rural areas, the majority of health facilities are concentrated in select large cities. India also depends on imports for higher-end medical products such as cancer diagnostics, medical imaging tools, amongst others. With the Government emphasizing early diagnosis of Non-Communicable Diseases (NCDs) and self-reliance, through Ayushman Bharat, there is an increased demand for advanced medical devices. The Revolution Aspire CT aims to address this need and enable access to quality medical equipment across India, including tier 2 and tier 3 cities.

The Revolution Aspire CT scanner empower clinicians with increased operational efficiency with upto 50% higher throughput*. The rotation time in Revolution Aspire CT scanner has been increased by 20%, enabling clinicians to provide faster diagnosis*. That along with a significantly improved cooling rate, the scanner allows a higher rate of continuous scanning and can handle higher patient volumes per day. The CT scanner also comes with a new detector design and algorithm, along with smart features such as Smart MAR, that enables up to 30% improved image quality*. As one of the most powerful systems in its segment, the system is redesigned to deliver higher performance through tube capacity, tube current, and X-ray generator power while maintaining the same footprint. Additionally, it provides intelligent IQ to provide exceptional clinical outcomes, besides reduced radiation dosage for patients and clinicians’ safety.

Commenting on the launch, Dr. Devi Shetty, Chairman and Senior Consultant Cardiac Surgeon said, “Access to healthcare has been deeply asymmetric in India and innovative medical technology products will help bridge this gap. We are witnessing this change with cutting-edge, locally manufactured, and affordable products such as the Revolution Aspire CT scanner helping democratize the market, taking quality healthcare to tier 2 cities and beyond. It is critical for all health centres, big and small, to have access to quality diagnosis. I applaud Wipro GE Healthcare’s endeavour to empower India’s healthcare infrastructure with this revolutionary product for improved patient care delivery.”

Dr. Shravan Subramanyam, Managing Director, Wipro GE Healthcare said, “We at Wipro GE Healthcare are committed to India’s vision of self-reliance. With Revolution Aspire CT system we aim to cater to the underserved markets and bridge the access gap to quality healthcare. We look forward to aligning closely with the government and will continue to invest medical devices ‘made in India, for India and for the world’; and advance our mission of enabling ‘healthcare for all.”

Srikanth Suryanarayanan, Head – Imaging, GE Healthcare, said, “We are very proud to launch the Revolution Aspire CT scanner – our ‘made in India’ product. It is one of our most efficient CT scanners and has been designed with accessibility in mind. With an increasing burden on the healthcare sector following the impact of COVID-19, healthcare institutions need advanced medical devices - more than ever before, for faster and more accurate diagnosis. Our new CT, is a powerful system that empowers the clinicians as well as the patients with greater efficiency, better results and higher comfort.”

The Revolution Aspire CT scanner is developed to ensure that the patient experience is seamless and stress-free. The scanner is equipped with a 70cm gantry bore aperture that can accommodate a diverse set of patients and an enhanced user interface which reduces preparation time and improves comfort. It is also incorporated with GE Healthcare’s ASiR technology which supports a lower radiation dose by 40%*, keeping patient safety in mind. Created as a future-ready product, the Revolution Aspire CT is built to be scalable with evolving needs of healthcare institutions.

The Revolution Aspire CT scanner has been manufactured at the recently launched Wipro GE Medical Device Manufacturing factory (MDM). The factory is one of 15 medical device manufacturers approved under the government’s PLI Scheme. Aligned to the National Agenda of ‘Atmanirbhar Bharat’, Wipro GE healthcare has invested a little over INR100 crore in this facility and aims to further boost local manufacturing of medical devices in India. The plant is a 100% subsidiary of Wipro GE Healthcare and has been setup as a green field legal entity.

About Wipro GE Healthcare:

Wipro GE Healthcare Private Limited is a Joint Venture (JV) between General Electric Company, USA and Wipro Enterprises Limited, India. Established in 1990, it is one of the most successful and longest-running JVs in the region with operations spread across India, Bangladesh, Sri Lanka, Nepal, Maldives and Bhutan. The company is the largest Medical Technology player in the South Asia region. Wipro GE is focused on addressing some of the toughest healthcare challenges - lowering maternal and infant deaths, enabling early detection of cancer, addressing heart diseases.

1 *Compared to previous generation CT scanner

SPECTRUM Digitizers and AWGs now support NVIDIA ClaraT

NVIDIA-Clara rear

Spectrum Instrumentation now offers driver support for the NVIDIA Clara AGX™, a universal computing architecture for the next generation of AI medical instruments. The new drivers enable scientists and developers to choose from 64 different Spectrum Digitizers, Arbitrary Waveform Generators (AWGs) and Digital I/O cards, letting the NVIDIA Clara AGX kit perform high-speed electronic signal acquisition and generation for analog and digital signals. With the big variety of cards to choose from, users can exactly match their electronic signal requirements.

For example, the digitizer cards can be used to acquire signals in the DC to GHz frequency ranges by sampling them at rates from 5 MS/s up to a maximum of 5 GS/s. Similarly, the AWG cards can be used to produce signals with almost any wave shape and frequency content, from DC to 400 MHz, by outputting samples at speeds from 40 MS/s up to 1.25 GS/s. Individual analog cards offer one, two, four or eight channel capability. Digital I/O cards and Digital Data Acquisition cards allow the acquisition of digital data at rates up to 720 MS/s and can generate digital patterns at up to 125 MS/s. There are different interface options for TTL and LVDS available.

The NVIDIA Clara AGX developer kit provides an easy-to-use platform for developing software-defined, AI-enabled, real-time, point-of-care medical devices. It delivers real-time streaming connectivity and AI inference by combining the flexibility of the NVIDIA® Jetson AGX Xavier™ embedded Arm® system on a chip (SoC), the performance of the integrated NVIDIA RTX™ 6000 GPU, and the 100 GbE connectivity of the NVIDIA ConnectX® SmartNIC, Clara AGX. The kit also includes full-stack GPU-accelerated libraries, SDKs, and reference applications for developers, data scientists, and researchers to create real-time, secure, and scalable solutions.

Adding a Spectrum card to the Clara system allows sensor signals to be acquired, generated, stored and processed. Data can be streamed between the cards, the processor and the GPU. In fact, the high-speed parallel processing capabilities of the GPU make it the perfect platform for handling the large volumes of data that can be acquired and generated by the Spectrum products. Spectrum already offers SCAPP (Spectrum's CUDA Access for Parallel Processing) to make GPU-based data processing easily achievable, even at the fastest streaming rates.

M4i.6631-x8

 
Looking at some examples: One or two cards of the M2p-series (5 MS/s to 125 MS/s) can be installed into the kit, as in Pic 2. The AWG signal generator card with 4 channels and the digitizer with 8 channels are running fully synchronized at a speed of 125 MS/s on all channels. Choosing one card of the ultra-fast M4i-series, such as the popular M4i.6631-x8 in Pic 3, turns the kit into an extremely low-noise AWG with signal generation up to 1.25 GS/s output speed on two channels. Another example uses the M4i.2212-x8 digitizer card that is already a core part of the world's first, high-throughput cell sorter created by the University of Tokyo in 2019. It allows signal acquisition up to 1.25 GS/s on four channels, with up to 3.4 GBytes per second streaming and high-speed processing via Spectrums SCAPP drivers and the internal NVIDIA RTX 6000 GPU of the Clara kit.

The NVIDIA Clara is already being used in a number of biomedical research programs and next generation of medical devices. Applications include imaging, genomics, patient monitoring, and drug discovery. It can be found everywhere the healthcare industry is innovating and accelerating the journey to precision medicine. Now, by installing a Spectrum card, or cards, this powerful platform has an easy way to acquire and generate the fast electronic sensor signals that are often found in this cutting-edge field.

Oliver Rovini, Chief Technical Officer at Spectrum, said: "We were delighted to be approached by NVIDIA, and partner with them to develop drivers for their NVIDIA Clara platform. Spectrum already has many customers using our technology in medical science. Now, together with the NVIDIA Clara, they have an easy way to create very small, low power systems, that offer some of the most advanced data processing tools available today."

Like all products by Spectrum Instrumentation, the 64 different M2p- and M4i-series cards carry a 5-year product warranty, with free software and firmware updates, as well as customer support directly from the engineering team, for the whole lifetime of the product. For more information, please visit:

www.spectrum-instrumentation.com

All trademarks are the property of their respective owners.

Ear Cleaning Gadget 'Cleansify', An Ear Otoscope for Ear Cleaning Launched By Portronics

Comes with 1080 FHD camera and LED Flash Light

Hygiene becomes a task, especially if it is for something as delicate as ears. This can become a serious issue of hygiene in adults as well as in children since they usually refrain from getting their ears cleaned. Moreover, earbuds are not exactly the safest way to ensure clean ears. Having a device that is safe and even gives a peek inside to check for ear wax or any possible infection, makes the task easier. Today, Portronics has launched “Cleansify”, an ear otoscope.

The ear microscope works at a frequency of 2.4Ghz, allowing for a fluid functioning of the ear camera. The ear camera has an ultra-fine 4.5mm lens that allows you to have a crystal clear view of the eardrums and the innate wall of the ear cavity. Besides, it gives a much clearer preview of the ear wax covering the walls of the cavity. 

Portronics Cleansify Ear Endoscope Otoscope/Wax Cleaner with 1080p FHD Camera with Ultra fine 4.5mm Lens for Kids & Adults(Black)

Cleansify has a 3 Megapixels endoscope which makes for the best quality of live time shots of the inner ear cavity. This is a top-end version of endoscopes and makes for the perfect ear cleaning device.

A 1080 FHD camera is a great add-on for such a device that usually gives out sketchy impressions. This feature will give you shots that are straight away pixels perfect and glitch-free! Cleansify comes with a 3 Axis Gyroscope, this feature defines the product in its entirety! Gyroscope is a tech that allows for angular orientation or in simpler words allows for angled views as compared to the general line of sight! 

The Portronics Cleansify has 300mAh powerful rechargeable battery that not only empowers the device but also makes it a perfect fit for the long run. The battery can be charged through any USB cable. In hindsight, the battery strength ensures the wellness and longevity of the device.

Portronics Cleansify comes with LED flash for a proper view of the inner ear cavity. The device tip is screw secured and would not detach while in action. Usually, the tips are just mounted on the edge, which comes off if extra force is applied. The ear camera can be controlled at the mere ease of an app. The App can be downloaded from the Playstore and Appstore and explored further. The device works in perfect sync with the app, Cleansify will safely do the job!

Pricing and Availability:

Portronics Cleansify is priced at INR 1,999 and can be purchased from Amazon.in, Portronics.com, and other leading online and offline stores and comes with a 12-month warranty.

About Portronics:

Portronics, standing for Portability and Innovation, has been a market leader in the digital & portable consumer electronics market space in India, for a long time now. A pioneer in innovative technology for the Indian demographic, Portronics has been touching and transforming the lives of its customers, by continuing to the tech space with new, quality gadgets. 

A firm believer in the power of good user experience, Portronics is synonymous with portability and high-functioning designs, due to an innovative product base and consumer satisfaction. With a PAN India presence, Portronics has been successfully delivering innovation at your doorstep for over 10 years and is constantly working up the ladder of transformation.

IIT Ropar Develops 1st-of-Its-Kind Oxygen Rationing Device - AMLEX

To increase the life of medical oxygen cylinders three fold, the Indian Institute of Technology, Ropar has developed a first-of-its-kind Oxygen Rationing Device – AMLEX that supplies a required volume of oxygen to the patient during inhalation and trips when the patient exhales CO2. This process saves oxygen which otherwise unnecessarily get wasted.

So far, during exhalation, the oxygen in the oxygen cylinder/pipe is pushed out along with the exhaled CO2 by the user. This leads to wastage of a large volume of oxygen in long run. In addition to this, a large volume of oxygen escapes from the openings of the mask to the environment in the resting period (between inhalation and exhalation) due to continuous flow of life saving gas in the mask. As we have seen the demand of medical oxygen has jumped manifold amid the second wave of Covid-19, the device would help in stopping the unwanted wastage of the same.

“The device can operate on both portable power supply (battery) as well as line supply (220V-50Hz)”, said Director, IIT, Ropar, Prof. Rajeev Ahuja.

It has been developed by PhD students of Biomedical Engineering Department of the institution - Mohit Kumar, Ravinder Kumar and Amanpreet Chander under the guidance of Dr. Ashish Sahani, Assistant Professor, Department of Biomedical Engineering.

“Made specifically for oxygen cylinders, AMLEX can be easily connected between oxygen supply line and the mask worn by the patient. It uses a sensor which senses and successfully detects inhalation and exhalation of the user in any environmental condition”, said Dr Sahani. This ready to use device works with any commercially available oxygen therapy masks having multiple openings for air flow.

Appreciating the innovation, Dr GS Wander, Director, Research and Development at Dayanand Medical College, Ludhiana, said that in the present pandemic times we all have learnt the importance of effective and pertinent use of life saving Oxygen. He said though many hospitals are increasing their oxygen production capacity, a device like this can really help in limiting the use of oxygen in small rural and semi urban health centers.

Prof. Rajeev Arora said that the country now needs rapid but safe solutions to combat Covid-19. Since the virus is affecting the lungs and subsequently breathing system of the patient, the institution has not intended to go in for patenting of the device. He said rather the IIT would be happy to transfer this technology free of cost, in the interest of the nation, to those interested to go in for mass production of the device.

DBT-BIRAC Supported Startup Blackfrog Develops An IoT-based Portable Medical Refrigeration Device that Maintains Temperature for 12 Hrs

A Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC) -supported startup Blackfrog Technologies has developed Emvolio, a portable, battery-powered medical-grade refrigeration device that improves the efficiency of the immunization by strictly maintaining preset temperature for up to 12 hours, thus enabling the safe and efficient transportation of vaccines to the last mile.

Emvólio has a 2-litre capacity, enabling it to carry 30-50 vials, the standard for a daylong immunization campaign. The device also includes continuous temperature monitoring, location tracking, state-of-charge indication, communication with headquarters via live-tracking, and vital statistics for improved coverage.

Blackfrog is an ISO-13485 certified manufacturer of medical devices, and Emvólio has been designed in accordance with WHO-PQS E003 standards. Emvólio’s patented technology ensures that all contents in the cold chamber are blanketed in strictly temperature-controlled air. The underlying refrigeration mechanism is solid-state cooling with a smart PID (Proportional Integral Derivate) controller, which guarantees precise temperature maintenance without the risk of noxious refrigerant leakage or cross-contamination. The lack of motors/compressors or any moving parts enables low-maintenance operation. The unique design of Emvólio promises uniform cooling and minimal freeze-thaw cycles.

Due to its ability of the device to strictly maintain the temperature between 2°C and 8°C for up to 12 hours in the field, the device is being used as a platform for delivery of vaccines and all other biologicals like blood, serums, viral culture. The innovation solves the current challenge of last-mile vaccine delivery as currently iceboxes, which have no mechanism for temperature control and regulation, are being used. The absence of temperature control and regulation in iceboxes also poses the risk of accidental freezing and thawing, rendering the temperature-sensitive vaccines inefficacious.

This startup has received grants from BIRAC under SEED fund, BIG for the development of proof-of-concept, BIPP for developing an end-to-end vaccine traceability system and has also been supported through BioNEST incubators.

Blackfrog has a production capacity of 1500 units/month, and Emvolio is now being deployed across North-East India with necessary clearance from the National Health Mission. Till now, Blackfrog has also sold 200+ vaccines carriers across 5 states in India for safe last-mile delivery of vaccines.

Electronic Noses: The New Technology That Can Help Asthma Symptoms

According to The World Health Organization, India is comprised of 15-20 million Asthmatics and of these 15-20% are children. Despite this rampant spread and frequency, Asthma remains underreported and underdiagnosed, but what if we could be more aware of the allergens and pollutants that are irritants for those who suffer from asthma or other lung conditions? This is where technology, such as an electronic nose, might help. “An electronic nose is a device composed of an array of electronic chemical sensors and an appropriate pattern recognition system,” explains IEEE Member Yangong Zheng.

Electronic noses use sensors to identify a mixture of gases, also known as a breath print. “The mixture of gases in air could react with the surfaces of the chemical sensors, causing a change in conductivity,” says Zheng. “The changes are then converted into electrical signals that create a specific response pattern for the mixture of gases.”

This technology has the ability to compare gases in the air to previously learned breath prints. Air pollution and pollen form different response patterns, so the nose will be able to identify the differences.

CAN AN ELECTRONIC NOSE DETECT ASTHMA?

“Human breath is made of plenty of volatile organic compounds (VOC) molecules and concentration,” says Zheng. “The mixture of VOCs provides the fundamental information on the physiologic and pathologic processes related to respiratory diseases. The patients with asthma have particular VOCs in their breath.

“Exhaled breath analysis via electronic noses has demonstrated a fairly good discriminative capacity, cross-validated accuracy is higher than 90% for differentiated patients affected by asthma,” says Zheng.

This means that an electronic nose is capable of detecting if someone suffers from asthma or another respiratory condition. Once the nose understands the breath print, it can compare response patterns with different human breath.

Electronic noses are also capable of detecting other illnesses and chronic conditions through breath print monitoring. An IEEE article found that e-noses could be non-invasive diagnosis tools for monitoring chronic kidney disease and haemodialysis as well.

WHAT IS THE FUTURE OF ELECTRONIC NOSES?

Electronic noses are not available for purchase yet, but research and technology are making great strides.

“Breath analysis by electronic nose is definitely complex and challenging, but the clinical applications are so pivotal in ensuring its development,” says Zheng. “Breath analysis supplies the information on metabolism and microbiome of patients, and it is an invasive procedure with limited costs –I am sure it will play a key clinical role in the future.”

Currently, the biggest market for e-noses is North America, the market is growing at a CAGR of 11.8%, as the wide array of applications for electronic noses makes them a viable product. Across the globe, various researchers are looking into electronic noses and how they can aid in the betterment of medical science. In the future, this technology could potentially provide a breakthrough in various respiratory disorders – especially in India and help the country in its fight against Asthma.

DetelPro Launches Di-OXYPRO Oximeter with OLED Display at Rs. 999

DetelPro, the health, and hygiene vertical of Detel have introduced Di-OXYPRO- fingertip Pulse oximeter (SpO2) medical device for checking blood oxygen saturation levels and heart rate remotely. Presently, the shortage of supply of pulse oximeters has caused chaos. DetelPro is working towards bringing quality solutions yet economical to its customers. Priced at Rs 999, the DetelPro oximeter comes with an OLED display that shows real-time SpO2 reading. The company is also providing 2 free doctor consultations to only 4 members of the family on the purchase of an oximeter from https://detel-india.com/.

COVID-19 cases are surging and one thing that needs to be taken care of is the oxygen level in the body. Measuring SPO2 levels is useful for people with respiratory or cardiovascular conditions, sleep apnea, heavy snoring, as well as for infants who are recommended for regular SpO2 monitoring. With comparatively lower power consumption than other pulse oximeters & high accuracy, Di-OXYPRO provides two parameters SPO2 & Pulse rate.

Di-OXYPRO is the newest addition to DetelPro’s Make in India effort. DetelPro oximeter works with a couple of replaceable 2AAA batteries. Additionally, the oximeter automatically gets powered off when there is no signal for five seconds. It is quite easy to use and has a minimalistic design with an OLED display and a function key.

Commenting on the launch, Dr. Yogesh Bhatia, Founder, Detel said--

Having the right patient parameters and vitals in remote healthcare delivery is a problem that DetelPro aims to address. DetelPro is known for its quality & it is the key benchmark for any product – especially in the healthcare equipment space. Our products are designed and developed in India, addressing the customers' needs and what more they are looking for.

About DetelPro

DetelPro, the health, and hygiene vertical of Detel is the latest entrant in the PPE Space in India. Detel, which is a homegrown brand that has manufactured the world's most economical consumer goods, has forayed into PPE Space with its sub-brand DetelPro to augment the supply of PPE products amidst a growing demand to fight the COVID-19 crisis. The company has already launched 'Make in India' PPE gears such as Infrared Thermometer, Hand Sanitizer, Face Shields, Masks, Gloves, etc for the frontline workers and the individual at large.

Medical Device Security Market Value Anticipated To Reach US$ 7,947.9 Million By 2027: Acumen Research And Consulting

PUNE, India, March 30, 2021 (GLOBE NEWSWIRE) -- Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Medical Device Security Market– Global Industry Analysis, Market Size, Opportunities and Forecast, 2020-2027”

LOS ANGELES, March. 30, 2021 (GLOBE NEWSWIRE) – The Global Medical Device Security Market is expected to grow at a CAGR of around 8.1% from 2020 to 2027 and reach the market value of over US$ 7,947.9 Mn by 2027.

The global medical device security market is projected to experience significant growth over the forecast period from 2020 to 2027. Majorly, the increasing usage and demand of medical devices across the healthcare sector, is bolstering the need for the security of these devices in the global market. The increasing demand for services associated with medical device security across the globe is additionally propelling the market value.

The global medical device security market is segmented on the basis of component, security type, device type, end-user, and geography. Based on components, the market is bifurcated across solutions and services.

On the basis of security type, market segments include application security, endpoint security, network security, cloud security, and other security types. By device type, the market is divided across hospital medical devices, internally embedded medical devices, and wearable and external medical devices. Additionally, the end-users in the medical device security market include healthcare providers, medical device manufacturers, and healthcare payers. 

In 2019, North America dominated the medical device security market and the region is also projected to lead the market with maximum revenue share (%) throughout the forecast period. The presence of major players in the region is primarily supporting the regional market value. The increasing number of chronic disease patients in the US is supporting the demand for management devices. For instance, chronic disease management accounts for about one-third of all US healthcare spending. Remote monitoring devices are at high risk of cyber attacks because these devices enable attackers to track the activity and health information of individuals over time. Moreover, this is also expected that the stolen information of the US employees can be used for espionage purposes. 

VIEW TABLE OF CONTENT OF THIS REPORT@ https://www.acumenresearchandconsulting.com/medical-device-security-market

Asia Pacific is anticipated to experience the fastest growth with major CAGR (%) over the forecast period from 2020 to 2027, especially due to its emerging economies and developing healthcare sector. The developing medical device and technology sector of the region is primarily bolstering the regional market value. Moreover, the increasing focus of major global players in the region particularly due to increasing opportunities is contributing to the regional market growth. 

Some of the leading competitors are Battelle Memorial Institute, Broadcom Inc., Cisco Systems, Drägerwerk AG & Co. KGaA, Extreme Networks, GE Healthcare, IBM, Koninklijke Philips N.V, Microsoft, Philips, and UL, LLC. The major players are continuously involved in the research and development activities in order to expand their share and position in the domestic as well as international market.

Browse Upcoming Market Research Reports@ https://www.acumenresearchandconsulting.com/forthcoming-reports

Some of the key observations regarding the medical device security industry include:

• Mayo Clinic has introduced some set of security requirements for its medical device suppliers. According to the new set of requirements, before signing the purchasing contracts each device gets tested to meet the standards before making a purchase decision.
  
  
• Vail Health, a nonprofit community health system located in Eagle and Summit counties in Colorado was facing cybersecurity problems associated with the inconsistent medical-device security software and firmware patching. The organization has implemented monitoring tools in March 2021 which are able to capture a lot of information relating to the devices that are connected, and these tools also provide security alerts to the staff.
  
  
• A survey conducted with 40 senior executives at U.S. Fortune 1000 companies found that only 18% of respondents believed the security capabilities embedded within medical devices were strong, and 80% have of respondents have described medical device security as adequate.
  
  
• The U.S. Food and Drug Administration (FDA) has updated draft guidance on best practices in 2021 for medical device manufacturers. The guidelines were last released in October 2018 by the FDA.
  
  
• According to the Center for Devices and Radiological Health of FDA, the increasing use of the internet & network-connected devices, wireless & portable media, and the frequent electronic exchange of health information from medical devices, has increased the need for effective cybersecurity to ensure medical device functionality and safety. 
  

INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/2528

BUY THIS PREMIUM RESEARCH REPORT – https://www.acumenresearchandconsulting.com/buy-now/0/2528

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157

For Latest Update Follow Us:

https://twitter.com/AcumenRC

https://www.facebook.com/acumenresearchandconsulting

https://www.linkedin.com/company/acumen-research-and-consulting